To compare the outcomes of robotic-assisted (RARC) vs. open radical cystectomy (ORC) at a single academic institution. We retrospectively identified patients undergoing radical cystectomy for urothelial carcinoma of the bladder at our institution from 2007 to 2017.
Currently, there is no consensus with respect to the optimal platform or approach for performing targeted prostate biopsies. Whereas many investigators have previously compared transperineal (TP) and transrectal (TR) approaches across a variety of biopsy indications, this is the first study to compare TP and TR targeted biopsies using the same fusion biopsy platform (UroNav, […]
San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a leading molecular imaging diagnostics company, announced that their manufacturing partner Nucleis (Liege, Belgium) has manufactured and shipped their first patient doses of rhPSMA-7.3 (18F), an investigational Prostate-Specific Membrane Antigen (PSMA)-targeted radiohybrid PET imaging agent, currently under evaluation in clinical trials in men with newly diagnosed prostate cancer […]
BACKGROUND: The ALSYMPCA trial of α-emitter Ra-223 in symptomatic bone predominant mCRPC reported Ra-223 median overall survival (OS) of 14.9 months versus 11.3 months OS for placebo (1). Subsequently reported "real world" experience with Ra-223 in smaller mCRPC patient cohorts appeared less successful(2-3).
Upper tract urothelial carcinoma is a rare malignancy for which surgery provides definitive management. Open radical nephroureterectomy was the gold standard treatment, but laparoscopic and robot-assisted approaches are alternative options.
While radical orchiectomy remains the gold standard for testicular cancer, partial orchiectomy has become a well-accepted organ-sparing approach for benign testicular tumors in pre-pubertal patients.
We previously demonstrated the safety of doses up to 48 Gy in 4 fractions with stereotactic body radiotherapy (SBRT) in poor surgical candidates with localized renal cell carcinoma (RCC). In an additional expansion cohort, we aimed to assess the safety of further dose escalation to 48-60 Gy in 3 fractions.
Renal cell carcinoma (RCC) is the most common kidney malignancy that frequently leads to metastasis. Increasing evidence has shown that long non-coding RNAs (lncRNAs) play crucial roles affecting the progression of RCC.
In the present study, we retrospectively analyzed the records of surgical confirmed kidney cancer with renal cell carcinoma pathology in the database of the hospital. We evaluated the significance of cancer size by assessing the outcomes of proposed adaptive active contour model (ACM).
Currently, a new subclassification of the Pi-RADS 3 lesions and subgroups is being used: 3a (indolent or low-risk lesions with volume <0.5 ml) and 3b (significant or high-risk lesions with volume ≥0.
